Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007683 · ClinicalTrials.gov registry record · Phase 3
Warfarin and Antiplatelet Therapy in Chronic Heart Failure
A Phase 3 study of Heart Failure, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,587
- Enrollment target
- 20
- Study locations
NCT00007683 is a Phase 3 study of Heart Failure that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 1,587 participants, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00007683, a Phase 3 study of Heart Failure, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,587 participants
- Enrollment target
- 20
- Study locations
Study Summary
Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in patients with primary cardiomyopathy, and still others consider it more appropriate in patients with coronary artery disease (CAD). This absence of consensus reflects the lack of evidence in this area and different outlooks on the objectives of such therapy (e.g., prevention of arterial emboli or reduction in vascular events).
Conditions Studied
Interventions
- DRUG Aspirin
- DRUG Warfarin titrated to an INR of 2.5-3.0
- DRUG Clopidogrel 75
Study Locations (20)
California
- Rancho Los Amigos National Rehabilitation Center - Downey
- VA Central California Health Care System, Fresno - Fresno
- VA Medical Center, Loma Linda - Loma Linda
- VA Palo Alto Health Care System - Palo Alto
- VA Medical Center, San Francisco - San Francisco
- VA Greater Los Angeles HCS, Sepulveda - Sepulveda
- Cardiovascular Consultants, Walnut Creek - Walnut Creek
- VA Greater Los Angeles Healthcare System, West LA - West Los Angeles
Connecticut
- Cardiology Associates of Derby, P.C. - Derby
- St. Francis Hospital and Medical Center - Hartford
- VA Connecticut Health Care System (West Haven) - West Haven
Florida
- Florida Cardiovascular Research - Atlantis
- VA Medical Center, Bay Pines - Bay Pines
- North Florida/South Georgia Veterans Health System - Gainesville
Arizona
- Carl T. Hayden VA Medical Center - Phoenix
- Southern Arizona VA Health Care System, Tucson - Tucson
Alabama
- VA Medical Center, Birmingham - Birmingham
Arkansas
- Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock - No. Little Rock
Colorado
- VA Eastern Colorado Health Care System, Denver - Denver
District of Columbia
- VA Medical Center, DC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,587 participants |
| Start Date | 1998-10 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00007683
The ClinicalTrials.gov registry entry for NCT00007683 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,587 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (22% lower). The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Aspirin is the first listed.
NCT00007683 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT00007683 about?
NCT00007683 is a clinical study titled "Warfarin and Antiplatelet Therapy in Chronic Heart Failure". Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in patients with primary cardiomyo...
What is the current status of trial NCT00007683?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,587 participants. The study started on 1998-10. Estimated completion is 2004-12.
What conditions does trial NCT00007683 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT00007683?
The interventions under investigation include: Aspirin (DRUG), Warfarin titrated to an INR of 2.5-3.0 (DRUG), Clopidogrel 75 (DRUG).
Who is sponsoring clinical trial NCT00007683?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00007683 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.